Although the death rates from coronary heart disease
|
|
- Antonia Watts
- 5 years ago
- Views:
Transcription
1 Effectiveness of Ezetimibe Monotherapy in Patients With Hypercholesterolemia Howard S. Friedman, PhD, MMS; Srinivasan Rajagopalan, PhD; Jaime P. Barnes, SM; and Robert D. Prentice, MB, ChB, FRCGP At a Glance Practical Implications p 268 Author Information p 273 Full text and PDF Disease Management Although the death rates from coronary heart disease (CHD) have declined over the years, CHD is still the leading cause of mortality in the United States. 1,2 In 24, CHD accounted for 869,724 deaths in the United States alone. 1 In addition, the economic burden of CHD is increasing, with total direct and indirect costs in the United States estimated at $448.5 billion for Hyperlipidemia is recognized as a major modifiable risk factor for CHD, particularly when it occurs in association with other risk factors such as hypertension, smoking, and diabetes. 3,4 A strong correlation between elevated levels of low-density lipoprotein cholesterol (LDL-C) and increased risk of CHD has been well established. 4 Clinical trials have shown that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) can significantly lower LDL-C levels and reduce CHD-related morbidity and mortality. 5-9 These findings have led to the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) guidelines and the American Heart Association/American College of Cardiology (AHA/ACC) guideline update (26) for aggressive cardiovascular risk management. 4,1 The NCEP ATP III guidelines placed patients with CHD into 5 risk categories, each with specific LDL-C treatment goals. The AHA/ACC 26 guideline update states that the target LDL- C goals for all patients with CHD and other clinical forms of atherosclerotic disease should be less than 1 mg/dl and that it is reasonable to treat such patients to a goal of less than 7 mg/dl (Table 1). 4,1 Patients with established CHD and other clinical forms of atherosclerotic disease are in the very high risk category and those without atherosclerotic disease but with CHD risk equivalents are in the high-risk group. Patients without CHD risk equivalents are at moderate risk, and patients with zero to one (-1) risk factor are in the lowest-risk group. CHD risk equivalents include diabetes and multiple risk factors that confer a 1-year risk ABSTRACT Objective: To evaluate the effectiveness of ezetimibe monotherapy for patients with moderate- to very high risk hypercholesterolemia in a managed care setting. Study Design: Retrospective analysis using administrative claims data from a large, employer-sponsored, insurancebased medical, pharmacy, and laboratory database. Methods: Patients with newly fi lled prescriptions for ezetimibe were identifi ed from July 1, 24, through December 31, 27. Patients were insured health plan members 18 years old or older with pharmacy benefi ts who were continuously enrolled for 6 months before and 3 months after initiating ezetimibe. The Wilcoxon signed rank test was used to evaluate changes in lowdensity lipoprotein cholesterol (LDL-C) measurements. The proportion of patients reaching their target American Heart Association/American College of Cardiology guideline (26) LDL-C goal was calculated. Adherence to ezetimibe was estimated from prescription refi lls. Results: The average percent LDL-C decline within 1 to 3 months of initiating ezetimibe was 18.5% ± 18.2% in the total population (P <.1 comparing baseline with postindex measurements); results for the diabetic subcohort were similar (17.4% ± 19.4%, P <.1 comparing baseline to postindex measurements). Approximately 35% of the total population and 3% of the diabetics reached their target LDL-C goal within 1 to 3 months of initiating ezetimibe. Patients with adherence (percent days covered) 75% or greater had higher percentage reductions in LDL-C than patients with adherence less than 5% (P <.1). Conclusions: Ezetimibe is an effective LDL-C lowering agent in patients with moderate- to very high risk hypercholesterolemia, including diabetics, in a managed care setting. It may offer an alternative for statin-intolerant patients. (Am J Pharm Benefi ts. 21;2(4): ) Vol. 2, No. 4 The American Journal of Pharmacy Benefi ts 267
2 n Friedman Rajagopalan Barnes Prentice PRACTICAL IMPLICATIONS This retrospective study compared the effectiveness of ezetimibe monotherapy for lowering low-density lipoprotein cholesterol (LDL-C) in a managed care population with results obtained in clinical trials. n Ezetimibe monotherapy appeared to have similar efficacy in clinical practice and clinical trials. n Results from this study reconfirmed that better adherence to therapy improved patients ability to reach their target LDL-C goals. n Managed care intervention programs may benefit by offering initiatives that improve medication adherence in patients with hypercholesterolemia. for CHD that is greater than 2%. In addition to reducing LDL-C levels to less than 1 mg/dl, an LDL-C level less than 7 mg/dl is a reasonable therapeutic goal for all patients at very high risk of myocardial infarction or death. 4,1 Several studies have reported poor goal attainment in CHD populations treated in clinical practice 11,12 ; these patients are far less likely to achieve LDL-C targets than those treated in clinical trials. 13 Frolkis et al compared expected LDL-C lowering based on the package inserts of atorvastatin, simvastatin, and pravastatin with the actual reductions achieved by hyperlipidemic patients in a preventive cardiology practice. 14 The mean observed reduction in LDL-C of 26% (±2%) was significantly lower than the expected reduction of 34% (±7%). 14 Treatment in clinical practice is rarely delivered as effectively or uniformly as in controlled efficacy trials. Factors such as population heterogeneity, patient adherence, and actual costs of treatment to the patient all contribute to the discrepancy seen between efficacy and effectiveness studies. 15 Table 1. LDL-C Goals as a Function of Risk Category a Risk Category Very high risk LDL-C Goal, mg/dl <7 b High risk <1 Moderately high risk <1 c Moderate risk <13 Low risk <16 AHA/ACC indicates American Heart Association/American College of Cardiology; LDL-C, low-density lipoprotein cholesterol. a According to the 26 AHA/ACC guidelines. b Optional goal; standard goal is 1 mg/dl. c Optional goal; standard goal is 13 mg/dl. Studies with statins have shown there is a lack of adherence to treatment by patients with CHD, and patient adherence worsens over time A significant portion of these patients are reluctant to take statins because of associated musculoskeletal symptoms, or as a result of reports in the media regarding myopathy. 19 Myopathy and rhabdomyolysis have been rarely reported for all statins, 2,21 and fatal rhabdomyolysis has been reported for all statins except fluvastatin. 22 Polypharmacy also can contribute to poor patient adherence, particularly in the elderly population, because of the higher number of drugs prescribed to elderly patients compared with the rest of the population. 23,24 Drug drug interactions have limited the use of statins in a number of patients, including patients taking select fibrates, protease inhibitors, and anticoagulants such as warfarin. 21 One specific example is the voluntary removal of cerivastatin from the market due to reports of fatal rhabdomyolysis particularly in association with gemfibrozil. 25 Current alternatives for patients with hypercholesterolemia who are intolerant to statins include bile acid sequestrants, niacin, and esters from plant sterols. Although these medications provide some reduction in LDL-C levels, the major barrier to their use is lack of patient compliance due to a range of associated side effects. 3 These data suggest the need for new interventions that are effective, safe, and well tolerated to increase the percentage of patients attaining LDL-C goals and, ultimately, to reduce the risk and burden of CHD. Ezetimibe has a mechanism of action different from that of other currently available lipid-lowering medications in that it aims to block cholesterol absorption at the intestinal brush border to reduce LDL-C levels without affecting absorption of triglycerides, lipid-soluble vitamins, or most concurrently administered medications. 26,27 The efficacy of ezetimibe monotherapy was demonstrated in a pooled analysis of 2 phase III clinical trials with a total of 1179 patients with primary hypercholesterolemia. Ezetimibe monotherapy significantly reduced mean LDL-C by 18.2% (P <.1) and resulted in a statistically significant small increase in high-density lipoprotein cholesterol (HDL-C) (1%; P <.1) and a statistically significant reduction in triglycerides ( 8.%; P <.1). Ezetimibe was well tolerated, with a safety profile similar to that of placebo. 28 As outlined above, several studies have found that patients receiving various lipid-lowering therapies do not achieve levels of LDL-C reduction in clinical practice similar to those obtained in clinical trials. In this study, we examined LDL-C lowering by ezetimibe monotherapy 268 The American Journal of Pharmacy Benefits August 21
3 Effectiveness of Ezetimibe Monotherapy in a managed care population to assess its effectiveness compared with the results obtained in clinical trials. METHODS A retrospective cohort study was conducted using administrative claims data from the 24 to 27 Ingenix Claims Database (i3 Innovus, Eden Prairie, MN). This database contains pharmacy and medical claims information for more than 2 million employed, commercially insured patients and their dependents, and laboratory results for approximately 15% of the population. Study Population Patients with newly filled prescriptions for ezetimibe were identified from July 1, 24, through December 31, 27. The period of study was from 6 months prior to the index date (the index date was the date of the first claim for ezetimibe) to 3 months following the index date. The length of time a patient was treated was variable between the index and postindex dates. A subcohort of patients with diabetes also was investigated. The study sample was selected from the population of insured health plan members age 18 years or older who had pharmacy benefits and were continuously enrolled throughout the study period. All patients included in the study had no previous claim for lipid-lowering therapy for at least 6 months prior to the index date, at least 1 LDL-C measurement within 6 months prior to the index date, and at least 1 LDL-C measurement between 1 and 3 months after the index date, and they had no change in their treatment regimen between the index date and the first posttreatment LDL-C measurement (months 1-3). Patients were categorized by risk level according to the updated AHA/ACC 26 guidelines, and only those in moderate-risk and high-risk categories were included. Patients identified as low risk for CHD (no CHD or CHD risk equivalents and -1 major CHD risk factors such as age, smoking, and family history of premature CHD) were excluded because of the potential misclassification of this risk category. As risk levels were assigned based on data provided by administration claims, a patient without CHD or CHD risk equivalents may be inadvertently classified as low risk because of the underreporting of certain risk factors such as smoking or family history of premature CHD. Patients who took medications that impact lipid levels or interact with ezetimibe at any time during the study period also were excluded. Patients could not have filled a prescription for any lipidlowering therapy including statins, ezetimibe, bile acid sequestrants, fibrates, and prescription-strength niacin Figure 1. Patient Selection Criteria and Resulting Sample Sizes First prescription of interest, July 1, 24, through December 31, 27 N = 163,244 Enrolled 6 months before, 3 months after index date and age 18 years or older on index date n = 91,463 No lipid-lowering therapies within 6 months before the index date n = 32,712 No liver disease n = 31,98 Only one strength on index date n = 31,968 LDL-C laboratory test within 6 months before the index date n = 7913 LDL-C laboratory test within 1-3 months after the index date n = 1895 No change in regimen, brand, or strength before the first post-treatment LDL-C measurement n = 167 No interacting drugs during the preindex and postindex periods n = 1138 No low-risk patients n = 663 No patients below goal at baseline n = 562 Diabetic subset of patients evaluated in the current study n = 227 LDL-C indicates low-density lipoprotein cholesterol. during the 6 months prior to the index date. Patients could not have filled a prescription for any lipid-lowering therapy besides ezetimibe during the time period from the index date to the first laboratory date. Patients with liver disease identified using the International Classification of Diseases, Ninth Revision, Clinical Vol. 2, No. 4 The American Journal of Pharmacy Benefits 269
4 n Friedman Rajagopalan Barnes Prentice Table 2. Patient Characteristics a Variable Total Population (N = 562) Diabetic Subcohort (n = 227) Demographics Female Age at baseline, mean ± SD, y 56.6 ± ± 1.4 Select comorbidities (during 18-day preindex period) Benign neoplasm Arthritis Cancer Depression or other affective and anxiety disorders Osteoporosis Renal failure Risk factors (used in determining revised 24 NCEP ATP III risk categorization) Age risk (male >45 years and female >55 years at baseline) Hypertension Diabetes Low HDL-C at baseline (<4 mg/dl) Chronic ischemic heart disease Stroke Angina Atherosclerosis Revascularization 2..4 Myocardial infarction Other acute and subacute ischemic heart disease NCEP ATP III indicates National Cholesterol Education Program Adult Treatment Panel III; HDL-C, high-density lipoprotein cholesterol. a Values represent number (percentage) unless indicated otherwise. Modification (ICD-9-CM) diagnostic codes, and patients at or below target LDL-C at baseline also were excluded (Figure 1). Optional goals were used for very high risk and moderately high risk patients (Table 1). Data Collection Data on variables related to ezetimibe therapy, adherence, and goal attainment were obtained from the medical claims database; these included demographics, cardiovascular history, and serum lipid levels. Information on demographic variables including sex and age was obtained from enrollment files. Drug use and prescription fill dates were obtained from the pharmacy claims database using National Drug Codes. Information regarding patients risk for CHD or CHD equivalents were obtained from the medical and pharmacy claims database prior to the index date using the AHA/ACC guidelines, ICD-9-CM codes, Current Procedural Terminology codes, and prescription records. Comorbidities were identified using the ICD-9-CM diagnostic codes during the 18-day time frame before the index date. Serum lipid level data for total cholesterol, LDL-C, HDL-C, and triglycerides were collected for 2 time periods: (1) baseline measurement taken within 6 months before the index date, and (2) postindex measurement taken 1 to 3 months after the index date. Attainment of the LDL-C goal was based on the 26 AHA/ACC guidelines (Table 1). Adherence was based on prescription refill activity, measured as the proportion of days covered by filled prescriptions for ezetimibe between the index date and the first postindex measurement. 29 For patients with multiple LDL-C laboratory values available within 1 to 3 months after the index date, the value from the first test following the index date was used for the adherence calculation. RESULTS Descriptive Analyses A total of 562 patients were identified as new ezetimibe users who were at moderate to high risk for CHD and met all the study inclusion criteria; lowrisk patients were excluded. From this population, a 27 The American Journal of Pharmacy Benefits August 21
5 Effectiveness of Ezetimibe Monotherapy Table 3. Outcome Measurements in the Total Population (N = 562) a,b Variable Baseline Lipid Measurements, mg/dl c Postindex Lipid Measurements, mg/dl d Change (Postindex Level Minus Baseline Level), mg/dl Total cholesterol ± ± ± ± 12.7 LDL-C ± ± ± ± 18.2 HDL-C 5. ± ± ± ± 12.1 Triglycerides ± ± ± ± 33. Other Outcome Measures 35.1 Percentage of patients reaching goal in 1-3 months Adherence e 85 ± 2 Days between index date and postindex 6.5 ± 17.5 lab measurement Percentage Change ([Postindex Level Minus Baseline Level]/ Baseline Level) HDL-C indicates high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol. a Values represent mean ± SD unless otherwise indicated. b Total population refers to the total sample meeting all of the inclusion criteria ( 2% of patients were missing total cholesterol, HDL-C, or triglyceride measurements). c Within 6 months before the index date (mean ± SD). d 1-3 months after the index date (mean ± SD). e The percentage of days covered between the index date and the first postindex measurement (based on prescription refill activity). Table 4. Outcome Measurements in the Diabetes Subcohort (N = 227) a Variable Baseline Lipid Measurements, mg/dl b Postindex Lipid Measurements, mg/dl c Change (Postindex Level Minus Baseline Level), mg/dl Total cholesterol ± ± ± ± 13.3 LDL-C ± ± ± ± 19.4 HDL-C 48.6 ± ± ± ± 12.9 Triglycerides 176. ± ± ± ± 32.4 Other Outcome Measures 29.5 Percentage of patients reaching goal in 1-3 months Adherence d 83 ± 2 Days between index date and postindex 62. ± 17.7 lab measurement HDL-C indicates high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol. a Values represent mean ± SD unless otherwise indicated. b Within 6 months before the index date (mean ± SD). c 1-3 months after the index date (mean ± SD). d The percentage of days covered between the index date and the first postindex measurement (based on prescription refill activity). Percentage Change ([Postindex Level Minus Baseline Level]/ Baseline Level) subcohort of 227 patients with diabetes also was identified (Figure 1). In the overall population, the most common comorbidities included hypertension, diabetes, low HDL-C (<4 mg/dl), chronic ischemic heart disease, and benign neoplasm. Similar trends were also seen within the diabetic subcohort (Table 2). Lipid Measurements The Wilcoxon signed rank test was used to evaluate changes in LDL-C measurements. Results showed a significant decrease in LDL-C values (P <.1) from baseline to postindex measurements. This finding was similar in both the total population and the diabetic subcohort (Table 3 and Table 4). The average percent LDL-C decline within 1 to 3 months of initiating ezetimibe monotherapy treatment was 18.5% ± 18.2% in the total population (Table 3). Measurements for the diabetic subcohort were similar, with an LDL-C decline of 17.4% ± 19.4% (Table 4). Analyses of the baseline and postindex LDL-C distributions show the decrease in LDL-C measurements for Vol. 2, No. 4 The American Journal of Pharmacy Benefits 271
6 n Friedman Rajagopalan Barnes Prentice Figure 2. Postindex LDL-C Distributions Show a Decrease in LDL-C Compared With Baseline for the Total Population (Panels A and B) and the Diabetic Subcohort (Panels C and D) A Patients B Patients C Patients D Patients <1 135 <1 1 <1 69 < Total Population Baseline LDL-C Measurement, mg/dl Total Population Postindex LDL-C Measurement, mg/dl Diabetic Subcohort Baseline Diabetic Subcohort Postindex both the total population and the diabetic subcohort (Figure 2). Based on the 26 AHA/ACC guidelines, approximately 35% of the total population treated with ezetimibe 55 LDL-C Measurement, mg/dl LDL-C Measurement, mg/dl LDL-C indicates low-density lipoprotein cholesterol >2 8 >2 11 >2 3 >2 monotherapy reached their target LDL-C goal within 1 to 3 months of initiating therapy. Approximately 3% of the diabetic subcohort also reached their target LDL-C goal within 1 to 3 months on ezetimibe monotherapy (Table 4). Adherence As seen in Figure 3, patients in the total population whose adherence rate (percent of days covered) was 75% or greater had statistically significant LDL-C reductions (P <.1), with an average of 2.% ± 16.3% decline from the baseline LDL-C measurement. Patients whose adherence was 75% or greater had higher percentage reductions in LDL-C than patients whose adherence was less than 5% (P <.1). DISCUSSION AND CONCLUSIONS This study demonstrates that ezetimibe is an effective LDL-C lowering agent in patients with moderate- to very high risk hypercholesterolemia, including diabetic patients in a managed care setting. Ezetimibe was associated with a mean LDL-C percent decrease from baseline to endpoint of 18.5% ± 18.2% in the overall population and 17.4% ± 19.4% in the diabetic subcohort. This decline in LDL-C is similar to rates previously reported in clinical trials ( 18%). 28 In addition, within 1 to 3 months of initiation of ezetimibe therapy, a reduction in triglycerides and a slight increase in HDL-C were observed in both the total population and diabetic subcohort (Tables 3 and 4). Increased levels of HDL-C and decreased levels of triglycerides have been reported to lower the risk of CHD. 3 The effectiveness of ezetimibe, as with other CHD medications, depends on patient adherence. 31 In the present study, overall patient adherence (based on prescription fill activity) was 85% in the total population and 83% in the diabetic subcohort (Tables 3 and 4). Patients with poor adherence rates had more limited LDL-C percent declines (Figure 3). Parris et al observed a similar relationship between adherence and LDL-C reductions in a study examining the relationship of adherence to statins and LDL-C goal attainment. 32 Of the 44% of patients in the Parris et al study who achieved their LDL-C goal, the mean adherence rate was 82% compared with a mean of 61% for the patients who did not attain their goal during the 9-month study. 32 Because this study was a retrospective analysis of an administrative claims database, several limitations should be taken into consideration. First, risk categories were assigned based on data provided by administrative claims. As such, patients without CHD or CHD risk 272 The American Journal of Pharmacy Benefits August 21
7 Effectiveness of Ezetimibe Monotherapy equivalents may have been inadvertently assigned to a risk level lower than their true medical condition due to underreporting of certain risk factors such as smoking or family history of premature CHD. That would have had no impact on the observed LDL-C change and percent LDL-C change, but would have resulted in a lower assigned LDL-C goal and a higher percentage of patients achieving that goal. To avoid this potential skewing of the analysis and confounding of the interpretation of the results, the analysis was limited to patients in the very high risk, high-risk, and moderate-risk categories. Additional limitations inherent to the current study include the following: (1) data regarding medication samples used by patients were not available in retrospective claims; (2) adherence was measured based on prescription fill activity rather than patient reporting; and (3) the sample size was limited, partially due to availability of LDL-C laboratory data. Despite these limitations, this study is able to offer insights into the effectiveness of ezetimibe monotherapy in reducing LDL-C levels in a managed care setting, and further emphasizes the importance of patient adherence for improved health-related outcomes. Although lowering LDL-C has a well-established relationship with reducing the risk of cardiovascular events, studies demonstrating the efficacy of ezetimibe with respect to clinical outcomes have not been completed, and the analysis of clinical outcomes was beyond the scope of the current study. The clinical benefit of ezetimibe is currently being evaluated in the IMPROVE-IT trial, where cardiovascular outcomes with simvastatin or simvastatin plus ezetimibe are being evaluated in patients with acute coronary syndrome. 33 IMPROVE-IT is expected to include approximately 18, patients and has an estimated completion date of June In conclusion, ezetimibe monotherapy may offer an important alternative for patients with hypercholesterolemia, including those with diabetes. It may be particularly useful for those who are intolerant to statins and those in whom statins are contraindicated. Author Affiliations: From Analytic Solutions, LLC (HSF), New York, NY; Med Data Analytics, Inc (SR), Williamsville, NY; Schering-Plough Pharmaceuticals (JPB), Kenilworth, NJ; and formerly of Blue Cross Blue Shield of North Carolina (RDP), Raleigh, NC. Funding Source: This study was funded by Merck and Company/ Schering-Plough Pharmaceuticals. Author Disclosures: Dr Friedman reports serving as a consultant for Schering-Plough Pharmaceuticals; Dr Rajagopalan reports serving as a consultant for Merck and Company; Dr Barnes reports being employed by and owning stock in Schering-Plough Pharmaceuticals; and Dr Prentice reports no relationship or financial interest with any entity that would pose a conflict of interest with the subject matter of this article. Figure 3. Relationship Between Adherence and Percent LDL-C Decline LDL-C Decline, % <5 (n = 56) 7.2 >5 <75 (n = 85) 18.4 Adherence, % LDL-C indicates low-density lipoprotein cholesterol. >75 (n = 421) 2. Authorship Information: Concept and design (HSF, SR, JPB, RDP); acquisition of data (SR); analysis and interpretation of data (HSF, SR, JPB); drafting of the manuscript (HSF, JPB, RDP); critical revision of the manuscript for important intellectual content (HSF, SR, JPB, RDP); statistical analysis (HSF, SR); obtaining funding (HSF, SR, JPB); and supervision (JPB). Address correspondence to: Howard S. Friedman, PhD, MMS, Analytic Solutions LLC, 26 Prince Street, Suite 2B, New York, NY howard@analytic-consulting.com. REFERENCES 1. Rosamond W, Flegal K, Furie K, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics 28 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee [published correction appears in Circulation. 21;122(1):e1. Kissela, Bret corrected to Kissela, Brett]. Circulation. 28;117(4):e25-e Mensah GA, Brown DW. An overview of cardiovascular disease burden in the United States. Health Aff (Millwood). 27;26(1): Stein EA. Managing dyslipidemia in the high-risk patient. Am J Cardiol. 22;89(5A):5C-57C. 4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 21;285(19): The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251(3): Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(2): Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(2): Cannon CP, Braunwald E, McCabe CH, et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes [published correction appears in N Engl J Med. 26;354(7):778]. N Engl J Med. 24;35(15): Vol. 2, No. 4 The American Journal of Pharmacy Benefits 273
8 n Friedman Rajagopalan Barnes Prentice 9. LaRosa JC, Grundy SM, Waters DD, et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 25;352(14): Smith SC Jr, Allen J, Blair SN, et al; AHA/ACC; National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 26 update: endorsed by the National Heart, Lung, and Blood Institute [published correction appears in Circulation. 26;113(22):e847]. Circulation. 26;113(19): Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2;16(4): Davidson MH, Maki KC, Pearson TA, et al. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol. 25;96(4): Davidson MH. Differences between clinical trial efficacy and real-world effectiveness. Am J Manag Care. 26;12(15 suppl):s45-s Frolkis JP, Pearce GL, Nambi V, Minor S, Sprecher DL. Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. Am J Med. 22;113(8): Streiner DL. The 2 Es of research: efficacy and effectiveness trials. Can J Psychiatry. 22;47(6): Benner JS, Pollack MF, Smith TW, Bullano MF, Willey VJ, Williams SA. Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy. Am J Health Syst Pharm. 25;62(14): Kulkarni SP, Alexander KP, Lytle B, Heiss G, Peterson ED. Long-term adherence with cardiovascular drug regimens. Am Heart J. 26;151(1): Mann DM, Allegrante JP, Natarajan S, Halm EA, Charlson M. Predictors of adherence to statins for primary prevention. Cardiovasc Drugs Ther. 27;21(4): Harper CR, Jacobson TA. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr Opin Lipidol. 27;18(4): Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother. 22;36(2): Armitage J. The safety of statins in clinical practice. Lancet. 27;37(961): Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med. 22;346(7): Egger SS, Ratz Bravo AE, Hess L, Schlienger RG, Krahenbuhl S. Age-related differences in the prevalence of potential drug-drug interactions in ambulatory dyslipidaemic patients treated with statins. Drugs Aging. 27;24(5): Gorard DA. Escalating polypharmacy. QJM. 26;99(11): Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med. 21;2(5): Davis HR, Veltri EP. Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. J Atheroscler Thromb. 27;14(3): Florentin M, Liberopoulos EN, Elisaf MS. Ezetimibe-associated adverse effects: what the clinician needs to know. Int J Clin Pract. 28;62(1): Knopp RH, Dujovne CA, Le Beaut A, Lipka LJ, Suresh R, Veltri EP; Ezetimibe Study Group. Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies. Int J Clin Pract. 23;57(5): Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 22;288(4): Davidson MH. Overview of prevention and treatment of atherosclerosis with lipid-altering therapy for pharmacy directors. Am J Manag Care. 27;13(suppl 1):S26-S Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 25;353(5): Parris ES, Lawrence DB, Mohn LA, Long LB. Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia. Diabetes Care. 25;28(3): ClinicalTrials.gov. IMPROVE-IT: Examining outcomes in subjects with acute coronary syndrome: Vytorin (ezetimibe/simvastatin) vs simvastatin (study P413AM3). show/nct22878?term=improve-it&rank=1. Accessed March 3, The American Journal of Pharmacy Benefits August 21
Extensive evidence exists that aggressive. Differences Between Clinical Trial Efficacy and Real-world Effectiveness REPORTS
Differences Between Clinical Trial Efficacy and Real-world Effectiveness Michael H. Davidson, MD, FACC, FACP Abstract Aggressive lowering of low-density lipoprotein cholesterol (LDL-C) with statin therapy
More informationCLINICAL. Determinants of Compliance With Statin Therapy and Low-Density Lipoprotein Cholesterol Goal Attainment in a Managed Care Population
Determinants of Compliance With Statin Therapy and Low-Density Lipoprotein Cholesterol Goal Attainment in a Managed Care Population Jennifer S. Schultz, PhD; John C. O Donnell, PhD; Ken L. McDonough, MD;
More informationCoronary heart disease (CHD) has. Clearfield The National Cholesterol Education Program Adult Treatment Panel III guidelines
the osteopathic physician. The treatment approach involves therapeutic lifestyle changes with diet, exercise, and weight loss. It requires regular, careful monitoring of serum cholesterol levels. The new
More informationReducing low-density lipoprotein cholesterol treating to target and meeting new European goals
European Heart Journal Supplements (2004) 6 (Supplement A), A12 A18 Reducing low-density lipoprotein cholesterol treating to target and meeting new European goals University of Sydney, Sydney, NSW, Australia
More informationThe new guidelines issued in PRESENTATIONS... Future Outlook: Changing Perspectives on Best Practice
... PRESENTATIONS... Future Outlook: Changing Perspectives on Best Practice Based on a presentation by Daniel J. Rader, MD Presentation Summary The guidelines recently released by the National Cholesterol
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationLearning Objectives. Patient Case
Joseph Saseen, Pharm.D., FASHP, FCCP, BCPS Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Learning Objectives Identify the 4 patient populations
More informationComparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients
Comparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients Cardiology Department, Bangkok Metropolitan Medical College and Vajira Hospital, Bangkok, Thailand Abstract
More informationIn 2001, the National Cholesterol Education Program
At a Glance Practical Implications p 330 Author Information p 333 Full text and PDF www.ajpblive.com Lipid Management When Converting Fluvastatin to Pravastatin: Medication Use Evaluation Original Research
More informationNearly 62 million people in the. ... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III
... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III Robert L. Talbert, PharmD Abstract Coronary heart disease (CHD) is a common, costly, and undertreated
More informationHYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016
HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 NOTHING TO DISCLOSE I, Nicole Slater, have no actual or potential conflict
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationB. Patient has not reached the percentage reduction goal with statin therapy
Managing Cardiovascular Risk: The Importance of Lowering LDL Cholesterol and Reaching Treatment Goals for LDL Cholesterol The Role of the Pharmacist Learning Objectives 1. Review the role of lipid levels
More informationSTATIN UTILIZATION MANAGEMENT CRITERIA
STATIN UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: HMG Co-A Reductase Inhibitors & Combinations Agents which require prior review: Advicor (niacin extended-release/lovastatin) Crestor (rosuvastatin)(5mg,10mg,
More informationData Alert. Vascular Biology Working Group. Blunting the atherosclerotic process in patients with coronary artery disease.
1994--4 Vascular Biology Working Group www.vbwg.org c/o Medical Education Consultants, LLC 25 Sylvan Road South, Westport, CT 688 Chairman: Carl J. Pepine, MD Eminent Scholar American Heart Association
More informationPCSK9 Agents Drug Class Prior Authorization Protocol
PCSK9 Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of medical
More informationDrug Class Monograph
Drug Class Monograph Class: Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Drugs: Praluent (alirocumab), Repatha (evolocumab) Line of Business: Medi-Cal Effective Date: February 17, 2016
More informationCoronary artery disease remains the leading
UNMET NEEDS IN THE TREATMENT OF ATHEROSCLEROSIS: WHY ARE WE NOT DONE YET? * Evan A. Stein, MD, PhD ABSTRACT Heart disease remains the leading cause of death in the United States. Despite advances in surgical,
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationIt is the policy of health plans affiliated with PA Health & Wellness that Vytorin is medically necessary when the following criteria are met:
Clinical Policy: Ezetimibe and Simvastatin (Vytorin) Reference Number: PA.CP.PMN.77 Effective Date: 02.01.17 Last Review Date: 07.18 Revision Log Description Ezetimibe/simvastatin (Vytorin ) contains ezetimibe,
More informationCholesterol Management Roy Gandolfi, MD
Cholesterol Management 2017 Roy Gandolfi, MD Goals Interpreting cholesterol guidelines Cholesterol treatment in diabetics Statin use and side effects therapy Reporting- Comparison data among physicians
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2062-8 Program Prior Authorization/Medical Necessity Medication Praluent (alirocumab) P&T Approval Date 5/2015, 8/2015, 9/2015,
More information( Diabetes mellitus, DM ) ( Hyperlipidemia ) ( Cardiovascular disease, CVD )
005 6 69-74 40 mg/dl > 50 mg/dl) (00 mg/dl < 00 mg/dl(.6 mmol/l) 30-40% < 70 mg/dl 40 mg/dl 00 9 mg/dl fibric acid derivative niacin statin fibrate statin niacin ( ) ( Diabetes mellitus,
More informationThe leading cause of death in the United States is coronary
Overcoming Inertia: Improvement in Achieving Target Low-density Lipoprotein Cholesterol Kenneth C. Goldberg, MD; Stephanie D. Melnyk, PharmD; and David L. Simel, MD, MHS Objective: To improve lipid management
More informationEffectiveness of statins in Medicare-eligible patients and patients < 65 years using clinical practice data*
ORIGINAL PAPER Effectiveness of statins in Medicare-eligible patients and patients < 65 years using clinical practice data* K. M. Fox, 1 S. K. Gandhi, 2 R. L. Ohsfeldt, 3 J. W. Blasetto, 4 M. H. Davidson
More informationQuality ID #438: Statin Therapy for the Prevention and Treatment of Cardiovascular Disease National Quality Strategy Domain: Effective Clinical Care
Quality ID #438: Statin Therapy for the Prevention and Treatment of Cardiovascular Disease National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE
More informationLipid Management Step Therapy Criteria with Medical Diagnoses Option*
Lipid Management Step Therapy Criteria with Medical Diagnoses Option* * Medical diagnoses are required for implementation of this option. Program may be implemented with the following options: Option One
More informationHae Sun Suh, B.Pharm., Ph.D. Jason N. Doctor, Ph.D.
Podium Presentation, May 18, 2009 Comparison of Cardiovascular Event Rates in Subjects with Type II Diabetes Mellitus who Augmented from Statin Monotherapy to Statin Plus Fibrate Combination Therapy with
More informationLipids & Hypertension Update
Lipids & Hypertension Update No financial disclosures Michael W. Cullen, MD, FACC Senior Associate Consultant, Assistant Professor of Medicine Mayo Clinic Department of Cardiovascular Diseases 34 th Annual
More informationLDL How Low can (should) you Go and be Safe
LDL How Low can (should) you Go and be Safe Edward Shahady MD, FAAFP, ABCL Clinical Professor Family Medicine Medical Director Diabetes Master Clinician Program Definition of Low LDL National Health and
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Statin Therapy Page 1 of 10 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Statin Therapy Prime Therapeutics will review Prior Authorization requests. Prior Authorization
More informationFrequency of Simvastatin Prescriptions With Potentially Interacting Medications in a Veterans Affairs Health Care System
ORIGINAL RESEARCH Frequency of Simvastatin Prescriptions With Potentially Interacting Medications in a Veterans Affairs Health Care System JERILYN B. PETROPOULOS, BSPharm, PharmD, BCPS, and CRISTINA E.
More informationClinical Policy: Pitavastatin (Livalo), Ezetimibe/Simvastatin (Vytorin 10/10 mg) Reference Number: CP.CPA.62 Effective Date:
Clinical Policy: Pitavastatin (Livalo), Ezetimibe/Simvastatin (Vytorin 10/10 mg) Reference Number: CP.CPA.62 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2063-8 Program Prior Authorization/Medical Necessity Medication Repatha (evolocumab) P&T Approval Date 5/2015, 9/2015, 11/2015,
More informationChanging lipid-lowering guidelines: whom to treat and how low to go
European Heart Journal Supplements (2005) 7 (Supplement A), A12 A19 doi:10.1093/eurheartj/sui003 Changing lipid-lowering guidelines: whom to treat and how low to go C.M. Ballantyne Section of Atherosclerosis,
More informationCoronary heart disease is the leading cause of death in
PHARMACOLOGY NOTES Ezetimibe (Zetia): a new type of lipid-lowering agent JIGNA PATEL, PHARMD CANDIDATE, VALERIE SHEEHAN, PHARMD, AND CHERYLE GURK-TURNER, RPH Coronary heart disease is the leading cause
More informationDrug Class Review HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin
Drug Class Review HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin Final Report Update 5 November 2009 This report reviews information about the comparative
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.HNMC.05 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy for important
More informationThe updated guidelines from the National
BEYOND NCEP ATP III: LESSONS LEARNED AND FUTURE DIRECTIONS * Benjamin J. Ansell, MD, FACP ABSTRACT The National Cholesterol Education Program (NCEP) Third Adult Treatment Panel (ATP III) guidelines provide
More informationSafety profile of atorvastatin-treated patients with low LDL-cholesterol levels
Atherosclerosis 149 (2000) 123 129 www.elsevier.com/locate/atherosclerosis Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels Rebecca G. Bakker-Arkema *, James W. Nawrocki,
More informationThe Framingham Coronary Heart Disease Risk Score
Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationInternational Journal of Research and Development in Pharmacy and Life Sciences. Research Article
International Journal of Research and Development in Pharmacy and Life Sciences Available online at http//www.ijrdpl.com February - March, 214, Vol. 3, No.2, pp 943-948 ISSN: 2278-238 Research Article
More informationHigh ( 50%) Restrictions mg 20-40mg PA; TS ⱡ 15 ⱡ
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Cholesterol P&T DATE: 5/9/2017 THERAPEUTIC CLASS: Cardiovascular REVIEW HISTORY: 5/16, 5/15, 2/14, 5/12, LOB AFFECTED: Medi-Cal
More informationSpending in the United States for prescription drugs was $216.7
Lipid Profile Changes Associated With Changing Available Formulary Statins: Removing Higher Potency Agents Daniel S. Longyhore, PharmD; Casey McNulty Stockton, PharmD; and Marie Roke Thomas, PhD Spending
More informationAchieving Cholesterol Management Goals: Identifying Clinician-Centered Challenges to Optimal Patient Care
Achieving Cholesterol Management Goals: Identifying Clinician-Centered Challenges to Optimal Patient Care Purpose Explore the adherence rates to cholesterol treatment targets among patients who seek care
More informationStatins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review.
ISPUB.COM The Internet Journal of Cardiovascular Research Volume 7 Number 1 Statins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review. C ANYANWU, C NOSIRI Citation C ANYANWU, C NOSIRI.
More informationAccumulating evidence suggests that intensive lipid lowering produces
Combination Therapy versus Monotherapy for Dyslipidemia: Are 2 Pills Better than 1? Accumulating clinical trial evidence and recently updated national guidelines support more aggressive efforts to reduce
More informationRECOGNITION OF THE METABOLIC SYNDROME
THE METABOLIC SYNDROME IN CLINICAL PRACTICE Michael H. Davidson, MD* ABSTRACT Patients with the metabolic syndrome remain at significantly elevated risk of morbidity and mortality associated with coronary
More informationThis is a lipid lowering drug strategy which should only be used within an overall lifestyle and clinical management strategy.
Treatment Guideline Statin Prescribing Objective These guidelines represent the views of the Gloucestershire Hospitals NHS Foundation Trust, which were arrived at after consideration of the available evidence
More informationDyslipedemia New Guidelines
Dyslipedemia New Guidelines New ACC/AHA Prevention Guidelines on Blood Cholesterol November 12, 2013 Mohammed M Abd El Ghany Professor of Cardiology Cairo Universlty 1 1 0 Cholesterol Management Pharmacotherapy
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club Announcements Next journal club Thursday, Dec. 14 th at 3:00 PM EST PACIFY Trial Effects of IV Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients
More informationPharmaceutical Help to Control Cholesterol
Pharmaceutical Help to Control Cholesterol Catherine E. Cooke, PharmD, BCPS, PAHM President, PosiHealth, Inc. Clinical Associate Professor, Univ. of Maryland This program has been brought to you by PharmCon
More informationPharmacology Challenges: Managing Statin Myalgia
Clinical Case: RM is a 50 year-old African American woman with a past medical history of type diabetes, dyslipidemia, hypertension and peripheral arterial disease. She had been prescribed simvastatin 80
More informationNew Guidelines in Dyslipidemia Management
The Fourth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2018 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationAchieving Lipid Goals: 2008 Update. Laura Hansen, Pharm.D. Associate Professor, University of Colorado School of Pharmacy
Achieving Lipid Goals: 2008 Update Laura Hansen, Pharm.D. Associate Professor, University of Colorado School of Pharmacy Discuss relationship between lipid values and coronary events Evaluate clinical
More informationREPATHA (PCSK9 INHIBITORS)
REPATHA (PCSK9 INHIBITS) Indications: PCSK9 Inhibitors are indicated for treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease as
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Vytorin) Reference Number: CP.PMN.77 Effective Date: 02.01.17 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationLipid Panel Management Refresher Course for the Family Physician
Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new
More informationAn update on lipidology and cardiovascular risk management. Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine
An update on lipidology and cardiovascular risk management Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine National and international lipid modification guidelines: A critical appraisal
More informationClinical Policy: Ezetimibe (Zetia) Reference Number: CP.PMN.78 Effective Date: Last Review Date: 02.19
Clinical Policy: (Zetia) Reference Number: CP.PMN.78 Effective Date: 02.01.17 Last Review Date: 02.19 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationMOLINA HEALTHCARE OF CALIFORNIA
MOLINA HEALTHCARE OF CALIFORNIA HIGH BLOOD CHOLESTEROL IN ADULTS GUIDELINE Molina Healthcare of California has adopted the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationDisclosures. Choosing a Statin/New Therapies. Case. How else would you do to treat him? LDL-C Reduction with Different Statin Strategies
Disclosures I have no disclosures relevant to this talk Choosing a Statin/New Therapies Aryan Aiyer, MD Assistant Professor of Medicine University of Pittsburgh School of Medicine UPMC Heart and Vascular
More informationStatin intolerance. Pr Franck Boccara, MD, PhD Cardiologie, INSERM UMRS938 CHU St Antoine, UPMC, Paris, France
Statin intolerance Pr Franck Boccara, MD, PhD Cardiologie, INSERM UMRS938 CHU St Antoine, UPMC, Paris, France Disclosure Statement of Financial Interest I currently have, or have had over the last two
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Overview
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Overview Ezetimibe for the treatment of primary (heterozygous familial and non-familial) hypercholesterolaemia The overview is written by members of
More informationLOW-DENSITY LIPOPROTEIN CHOLESTEROL GOAL ATTAINMENT AMONG MALAYSIAN DYSLIPIDEMIC PATIENTS
LOW-DENSITY LIPOPROTEIN CHOLESTEROL GOAL ATTAINMENT AMONG MALAYSIAN DYSLIPIDEMIC PATIENTS Alyaa AL-khateeb 1, Mohd Sapawi Mohamed 2, Kamarul Imran 3, Suhairi Ibrahim 4, BA Zilfalil1 1 and Zurkurnai Yusof
More informationModern Lipid Management:
Modern Lipid Management: New Drugs, New Targets, New Hope Kirk U. Knowlton, M.D Director of Cardiovascular Research Co Chief of Cardiology Why lower LDL C in those without evidence of CAD (primary prevention)
More informationOriginal paper. Abstract. Abdullah S. Asia 1*, Al-Mahdi A. Modar 2, Hadi M. Ali 3
Original paper Frequency Of Potential Adverse Effects Of A Semisynthetic Statin (Simvastatin) Compared To A Synthetic Statin (Atorvastatin) Used To Reduce Cardiovascular Risk For Patients In Basra 1*,
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Cer=fied Adult Nurse Prac==oner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Cer=fied Adult Nurse Prac==oner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationManagement of Post-transplant hyperlipidemia
Management of Post-transplant hyperlipidemia B. Gisella Carranza Leon, MD Assistant Professor of Medicine Lipid Clinic - Vanderbilt Heart and Vascular Institute Division of Diabetes, Endocrinology and
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More information4 th and Goal To Go How Low Should We Go? :
4 th and Goal To Go How Low Should We Go? : Evaluating New Lipid Lowering Therapies Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose
More informationJournal of the American College of Cardiology Vol. 54, No. 25, by the American College of Cardiology Foundation ISSN /09/$36.
Journal of the American College of Cardiology Vol. 54, No. 25, 2009 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.10.005
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationIn May 2001, the National Cholesterol. Effective Management of Patients With Dyslipidemia REPORT. Robert J. Lipsy, PharmD
REPORT Effective Management of Patients With Dyslipidemia Robert J. Lipsy, PharmD Abstract Coronary heart disease (CHD) is the leading cause of morbidity and mortality in the United States. A direct relationship
More informationConflicts of interest. What's the Skinny on the Lipid Guidelines? Key Differences. Are you applying the new ACC/AHA Lipid guidelines in your practice?
Conflicts of interest What's the Skinny on the Lipid Guidelines? The presenter has no relevant conflicts of interest to disclose. Kathleen Vest, PharmD, CDE, BCACP At the end of this presentation, pharmacist
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Caduet) Reference Number: CP.CPA.237 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationNew Guidelines in Dyslipidemia Management
The Third IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2017 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationPharmacy Policy Bulletin
Pharmacy Policy Bulletin Title: Policy #: PCSK9 inhibitors Rx.01.170 Application of pharmacy policy is determined by benefits and contracts. Benefits may vary based on product line, group, or contract.
More informationADMINISTRATIVE POLICY AND PROCEDURE
ADMINISTRATIVE POLICY PROCEDURE Policy #: Subject: PCSK9 INHIBITS (ex: Repatha) Section: Care Management Effective Date: January 1, 2015 Revision Date(s): NA Review Date(s): NA Responsible Parties: Patryce
More informationPreventing Myocardial Infarction in the Young Adult in the First Place: How Do the National Cholesterol Education Panel III Guidelines Perform?
Journal of the American College of Cardiology Vol. 41, No. 9, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0735-1097(03)00187-6
More informationDisclosures No relationships (not even to an employer) No off-label uses. Cholesterol Lowering Guidelines: What now?
Disclosures No relationships (not even to an employer) No off-label uses Cholesterol Lowering Guidelines: What now?, FACP 1 2 65-year-old white woman Total cholesterol 175mg/dL HDL 54 mg/dl LDL 96 mg/dl
More informationAPPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES
APPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES Main systematic reviews secondary studies on the general effectiveness of statins in secondary cardiovascular prevention (search date: 2003-2006) NICE.
More informationPharmacy Management Drug Policy
SUBJECT: ; Praluent (alirocumab), Repatha (evolocumab) POLICY NUMBER: Pharmacy-61 EFFECTIVE DATE: 8/15 LAST REVIEW DATE: 9/22/2017 If the member s subscriber contract excludes coverage for a specific service
More informationPIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia
PIEDMONT ACCESS TO HEALTH SERVICES, INC. Policy Number: 01-09-021 SUBJECT: Guidelines for Screening and Management of Dyslipidemia EFFECTIVE DATE: 04/2008 REVIEWED/REVISED: 04/12/10, 03/17/2011, 4/10/2012,
More informationCurrent Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD
Current Cholesterol Guidelines and Treatment of Residual Risk J. Peter Oettgen, MD Associate Professor of Medicine Harvard Medical School Director, Preventive Cardiology Beth Israel Deaconess Medical Center
More informationLipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology
Lipid Therapy: Statins and Beyond Ivan Anderson, MD RIHVH Cardiology Outline The cholesterol hypothesis and lipid metabolism The Guidelines 4 Groups that Benefit from Lipid therapy Initiation and monitoring
More informationMaking War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman
Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman Disclosures Research grant support, speaker/consulting honoraria: Sanofi and Regeneron Including ODYSSEY Outcomes
More informationQué factores de riesgo lipídicos debemos controlar? En qué medida?
Qué factores de riesgo lipídicos debemos controlar? En qué medida? Risk category High risk: CHD or CHD risk equivalents (10- year risk >20%) Moderately high risk: two or more risk factors (10-year risk
More informationDyslipidemia: Lots of Good Evidence, Less Good Interpretation.
Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. G Michael Allan Evidence & CPD Program, ACFP Associate Professor, Dept of Family, U of A. CFPC CoI Templates: Slide 1 Faculty/Presenter Disclosure
More informationIntroduction. Objective. Critical Questions Addressed
Introduction Objective To provide a strong evidence-based foundation for the treatment of cholesterol for the primary and secondary prevention of ASCVD in women and men Critical Questions Addressed CQ1:
More informationOver 800,000 Americans die from cardiovascular disease
Factors of Hyperlipidemia Medication Adherence in a Nationwide Health Plan Phillip Wiegand, PharmD, MS; Jeffery S. McCombs, PhD; and Jennifer J. Wang, PharmD, MS Over 800,000 Americans die from cardiovascular
More informationFarmaci innovativi in ambito cardiovascolare: considerazioni di Farmacologia. Prof. Alberto Corsini University of Milan, Italy
Farmaci innovativi in ambito cardiovascolare: considerazioni di Farmacologia Prof. Alberto Corsini University of Milan, Italy Outline of the presentation State of the art on statin therapy Explore unmet
More informationRosuvastatin: An Effective Lipid Lowering Drug against Hypercholesterolemia
ISPUB.COM The Internet Journal of Cardiovascular Research Volume 3 Number 1 Rosuvastatin: An Effective Lipid Lowering Drug against Hypercholesterolemia V Save, N Patil, G Rajadhyaksha Citation V Save,
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More information